Drugs / PNEUMOSTEM®
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07368088 | Mar → Dec 2026 expected | pulmonary arterial hypertension, pulmonary immaturity | Samsung Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT02274428 | Oct 2014 → Feb 2016 | — | Samsung Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01297205 | Dec 2010 → Sep 2011 | bronchopulmonary dysplasia | Medipost Co Ltd. | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT04003857 | Jul 2019 → Jun 2027 expected | bronchopulmonary dysplasia | Medipost Co Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03392467 | Aug 2018 → Jan 2024 | bronchopulmonary dysplasia | Medipost Co Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02890953 | Mar 2017 → Dec 2025 overdue | — | Samsung Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01828957 | Apr 2013 → May 2015 | bronchopulmonary dysplasia | Medipost Co Ltd. | Completed | Missed primary |
| Phase not applicable1 trial · 1 missed | ||||||
| — | NCT01897987 | Jan 2014 → Mar 2020 | bronchopulmonary dysplasia | Medipost Co Ltd. | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PNEUMOSTEM | “PNEUMOSTEM® is human umbilical cord blood derived mesenchymal stem cells and it is intended to treat premature infants with bronchopulmonary dysplasia.” NCT01297205 ↗ |
| Modality | Cell therapy | “allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation” PMID 24508444 ↗ Feb 2014 |
| Route | Other | “Single intratracheal administration” NCT01297205 ↗ |